
|Articles|October 31, 2012
SARcode reports phase III results for lifitegrast
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























